English
Our DNA
An innovative model serving essential medicines
At Juvisé Pharmaceuticals, our mission is to focus on essential medicines to improve the health of millions of patients worldwide.
A strategy centered on patient health and medication durability
Juvisé Pharmaceuticals is a pharmaceutical company with over 15 years of experience in acquiring and developing essential medicines
Pharmaceutical Research and Development is a long, complex and costly process. Only medications that have successfully navigated every stage are offered to patients.
Juvisé Pharmaceuticals has chosen to preserve existing princeps drugs, with proven therapeutic value, divested by other pharmaceutical companies looking to refocus on new molecules or other therapeutic areas.
Since our establishment in 2008, our portfolio has gradually grown and now includes 10 medications, 4 of which are listed on the WHO’s list of essential medicines, covering four main therapeutic areas: neuroscience, gastroenterology, oncology, and cardiology.
A networked organization
Our network model is designed to facilitate rapid growth and adaptability guaranteeing not only operational efficiency but also the highest standards in the production and distribution of our essential medications.
Our team of approximately 60 healthcare professionals, located between Paris and Lyon, plays a crucial role as orchestrators in managing various projects and external partners. These partners include manufacturing sites, distributors, Contract Sales Organisations (CSOs), and commercial partners.
We meticulously select each partner to ensure that they align with our rigorous standards and commitment to quality.
Our extensive expertise and carefully chosen partners allow us to maintain a dynamic and responsive infrastructure that upholds the quality and integrity of our medicines, ultimately benefiting patients and enhancing healthcare outcomes.
A strong international presence
Juvisé Pharmaceuticals has established itself as a leading international pharmaceutical company.
Leveraging our robust network of distributors, agents, and partners, we successfully market our medications in nearly 80 countries across the globe.
Our primary focus is on Europe, where we achieved 63% of our sales in 2023. We have a particularly strong presence in France, Germany, Italy, UK, Spain and Portugal. In these countries, we benefit from an extensive network of commercial partners, which allows us to stay close to healthcare professionals.
Additionally, we are actively engaged in the Middle East and Africa (MEA) region, where our pharmaceutical specialties are widely marketed, ensuring that essential medicines reach patients in these areas.
Overall, we are proud to contribute to the improvement of health for approximately 2.5 million patients worldwide each year.
European manufacturing: our commitment to quality and supply
By moving production closer to key markets, we can not only uphold rigorous quality standards but also enhance the reliability of supply chains.
Our model also contributes to protecting Europe’s health and industrial sovereignty as the majority of our medications are manufactured in Europe : 81% in 2023, with an ambitious goal of achieving nearly 100% by 2024.
With 18 manufacturing sites for finished products and 12 manufacturing partners for active ingredients, Juvisé Pharmaceuticals benefits from a solid network of industrial partners to produce the various pharmaceutical forms required (tablet, capsule, drop and injectable solution).
We believe that relocating pharmaceutical manufacturing to Europe is a crucial strategy for ensuring high-quality production while effectively addressing stock-out issues.
A recognized expertise
Juvisé Pharmaceuticals is a secure, reliable business partner recognized by major pharmaceutical companies (Novartis, AstraZeneca, AbbVie…), with which it has signed numerous agreements since its creation.
Juvisé Pharmaceuticals’ expertise is particularly renowned for the integration of new pharmaceutical products into our portfolio. Thanks to our networked model, talented team, and strong global partner network, we optimize the production and distribution costs of the drugs we acquire by relocating them to Europe. We then ensure their rapid relaunch and deployment through effective, targeted promotional campaigns.
JUV-FRA-202408-0213, 09/2024
From neuroscience to gastroenterology, our medications treat 2.5 million patients each year
Join Juvisé Pharmaceuticals and become part of a company that values excellence and commitment
From neuroscience to gastroenterology, our medications treat 2.5 million patients each year
Join Juvisé Pharmaceuticals and become part of a company that values excellence and commitment